Olfactory neuroblastoma and other round cell lesions of the sinonasal region.
Sixty-nine round cell lesions of the sinonasal region (22 olfactory neuroblastomas [ONBs], 17 malignant lymphomas, nine Ewing's sarcomas [ES], nine rhabdomyosarcomas, three sinonasal undifferentiated carcinomas, five malignant melanomas, and four pituitary adenomas) were studied in an attempt to define the differential diagnostic capabilities of antibody to MIC2 and bcl-2 in paraffin-embedded tissue in the distinction of these lesions. In addition, antibody to p53 was applied in each case to define the incidence of p53 positivity among these various tumor types. Each of the ES cases was MIC2 positive; each of the other cases was MIC2 negative. Positivity for bcl-2 was confined to two cases, one of them a malignant lymphoma (85% of cells positive) and one an ONB (5% of cells positive). Small numbers of scattered p53-positive cells appeared in the majority of cases studied, without regard for the specific tumor type; only a single case, a malignant lymphoma, showed a majority (approximately 90%) of p53-positive cells. These results indicate that the MIC2 antibody is a useful method by which to distinguish ES from a variety of other round cell lesions that may be encountered in the sinonasal region. The practical applications of antibody to bcl-2 and p53 seem to be much more limited; by contrast, neither bcl-2 positive cells nor abundant p53 cells identified by immunohistochemical analysis seemed to be frequent findings in any of the tumor types studied. Although ONBs have been included with the peripheral primitive neuroectodermal tumors for classification purposes, these tumors diverge from the ES/primitive neuroectodermal tumor family in that they do not seem to share either the MIC2 positivity or the t(11;22) chromosomal translocation that typify the ES/primitive neuroectodermal tumor family of lesions. Although bcl-2 positivity has been associated with a light microscopic finding of an unfavorable histologic pattern in retroperitoneal neuroblastomas, it does not seem that bcl-2 positivity in ONB will select for a clinically distinctive subset of patients.
Devaney
K
K
Department of Pathology, University of Michigan Hospitals, Ann Arbor 48109-0054, USA.
Wenig
B M
BM
Abbondanzo
S L
SL
D000071443:12E7 Antigen; D000236:Adenoma / Q000473:pathology; D015703:Antigens, CD / Q000032:analysis; D002277:Carcinoma / Q000473:pathology; D018288:Carcinoma, Small Cell / Q000473:pathology*; D015815:Cell Adhesion Molecules / Q000032:analysis; D003937:Diagnosis, Differential; D018304:Esthesioneuroblastoma, Olfactory / Q000737:chemistry / Q000473:pathology*; D006801:Humans; D007150:Immunohistochemistry; D008223:Lymphoma / Q000473:pathology; D008545:Melanoma / Q000473:pathology; D009296:Nasal Cavity; D009669:Nose Neoplasms / Q000737:chemistry / Q000473:pathology*; D010256:Paranasal Sinuses / Q000473:pathology; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000032:analysis; D012208:Rhabdomyosarcoma / Q000473:pathology; D012512:Sarcoma, Ewing / Q000473:pathology; D016159:Tumor Suppressor Protein p53 / Q000032:analysis
D000071443:12E7 Antigen; D015703:Antigens, CD; C061828:CD99 protein, human; D015815:Cell Adhesion Molecules; D019253:Proto-Oncogene Proteins c-bcl-2; D016159:Tumor Suppressor Protein p53